Addex-Led Consortium Receives €4.85 Million Eurostars Grant to Develop Novel Allosteric Modulator to Treat Post-Traumatic Stress Disorder (PTSD)
July 09, 2019 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, July 9, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that it will lead a...
Addex Shareholders Approve All Resolutions at Annual General Meeting
June 20, 2019 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, 20 June 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders...
Addex Annual General Meeting Scheduled for June 19, 2019
May 28, 2019 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, May 28, 2019 – Addex Therapeutics (SIX: ADXN) announced today that its Annual General Meeting will take place on Wednesday, June 19, 2019, at 11:00am at the Campus Biotech, Chemin...
Addex Increases Issued Share Capital and Creates Treasury Shares
May 20, 2019 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, May 20, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that it has increased its...
Addex to Present at the 28th Medtech Investing Europe Conference
May 08, 2019 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, May 8, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer will give...
Addex to Present During the Swiss Biotech Day
May 06, 2019 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, May 6, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer will...
Addex Reports 2018 Full Year Audited Results and Provides Corporate Update
April 30, 2019 01:00 ET
|
Addex Therapeutics
Robust cash position of CHF41.7 million providing runway through 2021Dipraglurant on track to start pivotal registration study in PD-LID by end of yearStrengthened team of clinical and preclinical...
Addex to Announce 2018 Full Year Audited Results on April 30, 2019
April 29, 2019 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, April 29, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that it will report its...
Addex to Participate in the BIOEurope Spring Conference
March 21, 2019 02:00 ET
|
Addex Therapeutics
Geneva, Switzerland, March 21, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer and...
Addex to Present at the Cowen 39th Annual Health Care Conference on March 13, 2019
March 11, 2019 02:00 ET
|
Addex Therapeutics
Geneva, Switzerland, 11 March 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that the company’s CEO,...